NASDAQ · BFRI
Biofrontera Inc.
$0.93+$0.05 (+5.09%)
Biofrontera Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.89% below the high.
Loading market information…
NASDAQ · EVOK · USD
Stock price, earnings
Quote as of Dec 17, 2025, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Evoke Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Evoke Pharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Evoke Pharma, Inc. operates as a specialized pharmaceutical entity, primarily focused on inventing and bringing to market therapeutic agents for various digestive system illnesses. The company's lead development candidate is Gimoti, a metoclopramide nasal spray, which has progressed through and completed its Phase 3 clinical trials. This medicine is being developed to mitigate symptoms associated with both acute and recurring diabetic gastroparesis, specifically in female patients. Evoke Pharma distributes its offerings to a broad base of healthcare professionals, encompassing digestive disease specialists, internists, general practitioners, and certain other medical providers. Established in 2007, the company's corporate offices are situated in Solana Beach, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2024 | May 14, 2024 | -$2.04-871.43% vs estimate | $1.74M-18.9% vs estimate |
|---|
| Q4 2023 | Mar 14, 2024 | -$7.08-1,316.0% vs estimate | $1.68M+2.82% vs estimate |
|---|
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.93+$0.05 (+5.09%)
Biofrontera Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.89% below the high.
$5.05+$1.34 (+36.12%)
Adial Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.41% below the high.
$1.74-$0.01 (-0.57%)
Biomerica, Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.82% below the high.
$3.33+$0.22 (+7.07%)
Sunshine Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.28% below the high.
$1.20+$0.06 (+5.26%)
Sonoma Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.07% below the high.
$6.86$0.00 (0.0%)
Meihua International Medical Technologies Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 75.14% below the high.
$0.39+$0.02 (+4.56%)
cbdMD, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.85% below the high.
$2.13-$0.23 (-9.75%)
NeuroSense Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 91.61% below the high.
